Mather Group
CRSP icon

Mather Group’s CRISPR Therapeutics CRSP Stock Holding History

Mather Group’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$12.3K Buy
+222
New +$12K ﹤0.01% 1590
2026
Q2 		– Sell
-35
Closed -$1.66K – 1923
2026
Q1 		$1.66K Buy
+35
New +$1.85K ﹤0.01% 1721
2025
Q2 		– Sell
-250
Closed -$8.51K – 850
2025
Q1 		$8.51K Hold
250
– – ﹤0.01% 1294
2024
Q4 		$9.8K Hold
250
– – ﹤0.01% 1252
2024
Q3 		$11.7K Sell
250
-150
-38% -$7.61K ﹤0.01% 1151
2024
Q2 		$27.3K Buy
400
+150
+60% +$8.68K ﹤0.01% 1185
2024
Q1 		$15.6K Buy
+250
New +$17.9K ﹤0.01% 1102

Other funds holding CRSP

Concurrent Investment Advisors
Concurrent Investment Advisors Tampa, Florida $14.5B AUM 24.52% 1-Year Est. Return
KBC Group
KBC Group Brussels, Belgium $47.9B AUM 37.61% 1-Year Est. Return
Congress Asset Management
Congress Asset Management Boston, Massachusetts $15.4B AUM 30.39% 1-Year Est. Return
NTV Asset Management
NTV Asset Management Charleston, West Virginia $1.08B AUM 23.94% 1-Year Est. Return
Green Alpha Advisors
Green Alpha Advisors Niwot, Colorado $148M AUM 98.22% 1-Year Est. Return
Hennion & Walsh Asset Management
Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return
Moran Wealth Management
Moran Wealth Management Naples, Florida $3.64B AUM 28.63% 1-Year Est. Return
Canal Insurance Company
Canal Insurance Company Greenville, South Carolina $426M AUM 30.47% 1-Year Est. Return
Bouvel Investment Partners
Bouvel Investment Partners Phoenixville, Pennsylvania $433M AUM 51.2% 1-Year Est. Return
Perigon Wealth Management
Perigon Wealth Management San Francisco, California $6.5B AUM 20.72% 1-Year Est. Return

Mather Group's CRSP Position: Q3 2026 in Review

Mather Group opened a new position in CRISPR Therapeutics (CRSP) in Q3 2026: 222 shares worth $12.3K. The stake represents ﹤0.01% of the portfolio and ranks #1590 among its holdings. This is a return to the name: Mather Group previously reported a position in CRSP as recently as Q1 2026.

Mather Group first reported a position in CRSP in Q1 2024 and has held it in 7 quarters since. The position peaked at $27.3K in Q2 2024. 78 funds tracked by Wall St. Rank hold CRSP as of Q3 2026.

  • Mather Group held 222 shares of CRISPR Therapeutics worth $12.3K as of Q3 2026.
  • CRISPR Therapeutics was a new Mather Group position in Q3 2026.
  • CRISPR Therapeutics made up ﹤0.01% of Mather Group's portfolio in Q3 2026, its #1590 holding.
  • Mather Group first reported a position in CRISPR Therapeutics in Q1 2024 and has held it in 7 quarters since.
  • Mather Group's CRISPR Therapeutics position peaked at $27.3K in Q2 2024.
  • 78 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q3 2026.

Based on Mather Group's 13F filing for Q3 2026, filed 14 Oct 2026.